Nexavar

Nexavar is a brand name of sorafenib, approved by the FDA in the following formulation(s):

NEXAVAR (sorafenib tosylate - tablet; oral)

• 
  Manufacturer: BAYER HLTHCARE
  
  Approval date: December 20, 2005
  
  Strength(s): EQ 200MG BASE ^[RLD]

Has a generic version of Nexavar been approved?

No. There is currently no therapeutically equivalent version of Nexavar available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nexavar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
  Patent 7,235,576
  Issued: June 26, 2007
  Inventor(s): Riedl; Bernd & Dumas; Jacques & Khire; Uday & Lowinger; Timothy B. & Scott; William J. & Smith; Roger A. & Wood; Jill E. & Monahan; Mary-Katherine & Natero; Reina & Renick; Joel & Sibley; Robert N.
  Assignee(s): Bayer Pharmaceuticals Corporation
  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
  
  Patent expiration dates:
  
  
  • January 12, 2020
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
  Patent 7,351,834
  Issued: April 1, 2008
  Inventor(s): Riedl; Bernd & Dumas; Jacques & Khire; Uday & Lowinger; Timothy & Scott; William & Smith; Roger A. & Wood; Jill E. & Monahan; Mary-Katherine & Natero; Reina & Renick; Joel & Sibley; Robert
  Assignee(s): Bayer Pharmaceuticals Corporation
  This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
  
  Patent expiration dates:
  
  
  • January 12, 2020
    
    ✓ 
    Drug substance
  
  



• 
  ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
  Patent 7,897,623
  Issued: March 1, 2011
  Inventor(s): Riedl; Bernd & Dumas; Jacques & Khire; Uday R. & Lowinger; Timothy B. & Scott; William J. & Smith; Roger A. & Wood; Jill E. & Monahan; Mary-Katherine & Natero; Reina & Renick; Joel & Sibley; Robert N.
  Assignee(s): Bayer Healthcare LLC
  This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
  
  Patent expiration dates:
  
  
  • January 12, 2020
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 16, 2010 - TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA
  
  
  • December 20, 2010 - NEW CHEMICAL ENTITY
  
  
  • December 20, 2012 - ORPHAN DRUG EXCLUSIVITY
  
  
  • November 16, 2014 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Nexavar Consumer Information (Drugs.com)
• Nexavar Consumer Information (Wolters Kluwer)
• Nexavar Consumer Information (Cerner Multum)
• Nexavar Advanced Consumer Information (Micromedex)
• Nexavar AHFS DI Monographs (ASHP)
• Sorafenib Consumer Information (Wolters Kluwer)
• Sorafenib Consumer Information (Cerner Multum)
• Sorafenib Advanced Consumer Information (Micromedex)
• Sorafenib Tosylate AHFS DI Monographs (ASHP)